Journal Updates
eMediNexus Coverage from: 
Shorter Combo Treatment OK in Stage III CRC
eMediNexus,  20 May 2019
remove_red_eye 502 Views
#Gastroenterology #Hematology #Oncology #Pharmacist #Radiology

0 Read Comments                

While a shorter duration of adjuvant chemotherapy does not appear to increase the risk of death in stage III colon cancer patients on combination regimens, those receiving monotherapy should have the entire 6 months of treatment, suggested the authors of a new meta-analysis published in JAMA Network Open.The meta-analysis of 22 studies involving 43,671 patients with stages II or III disease included two randomized trials and 20 observational studies. The authors noted
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now